Lawrence Yellin Appointed as Fuse Medical CFO

Fuse Medical Inc. has appointed Lawrence S. Yellin as chief financial officer (CFO) and Executive Board member. Yellin is now responsible for all financial functions in the company, including accounting, audit, treasury, corporate finance, SEC reporting, and investor relations.

“We are pleased to welcome Mr. Yellin to our executive team and believe that Larry’s experiences in corporate strategy, financial expertise, and SEC background will make him an excellent fit for Fuse,” CEO Christopher C. Reeg said. “As Fuse continues our mission of providing innovative medical devices to the orthopedic industry, we feel that Larry will prove to be a key factor of our growth through his proven track record in financial planning and his refined skills in business leadership.”
 
Yellin’s career spans more than 25 years of varied experience in financial management, business leadership, and corporate strategy. He served as CFO for NVIP LLC, a holistic health and wellness supplier and manufacturer, where he supervise financial activities that included liquidity risk management, asset and liability administration, cashflow tracking, financial planning, financial strengths and weakness analyzation, and corrective action proposals. Before joining NVIP LLC, Yellin was CFO for Logic E Cigarettes, where he helped the company grow and transition to a top tier e-cigarette company that was eventually sold to Japan Tobacco. Prior to that, Yellin was vice president and controller for Handy & Harman, a publicly traded holding company that owns and operates businesses in various industries, and CFO for Fujifilm’s Consumer Imaging Group.
 
Yellin earned a bachelor of science degree in accounting from Ohio State University, an MBA in finance from Pace University, and is a certified public accountant. 
 
Fuse is an emerging manufacturer and distributor of medical devices for the orthopedic and spine marketplace. It has a portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as degenerative and deformity spine, osteobiologics, wound care, and regenerative products.